Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124974183 | 12497418 | 3 | F | 2016 | 20160623 | 20160624 | 20160704 | EXP | US-ASTRAZENECA-2016SE69417 | ASTRAZENECA | 1.00 | YR | M | Y | 6.50000 | KG | 20160705 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124974183 | 12497418 | 1 | PS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 0 | INJECTION | ||||||||||
| 124974183 | 12497418 | 2 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 78 MG | 0 | INJECTION | |||||||||
| 124974183 | 12497418 | 3 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 92 MG | 0 | INJECTION | |||||||||
| 124974183 | 12497418 | 4 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 98 MG | 0 | INJECTION | |||||||||
| 124974183 | 12497418 | 5 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 104 MG | 0 | INJECTION | |||||||||
| 124974183 | 12497418 | 6 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 102 MG | 0 | INJECTION | |||||||||
| 124974183 | 12497418 | 7 | C | BIGAIA | 2 | EVERY DAY | 0 | ||||||||||||
| 124974183 | 12497418 | 8 | C | ALDACTONE | SPIRONOLACTONE | 1 | 0 | 14 | MG | QD | |||||||||
| 124974183 | 12497418 | 9 | C | OMEPRAZOL MUT | 2 | 5 MG | 0 | ||||||||||||
| 124974183 | 12497418 | 10 | C | VIGANTOLETTEN | CHOLECALCIFEROL | 1 | 500 IU | 0 | |||||||||||
| 124974183 | 12497418 | 11 | C | ASPIRIN. | ASPIRIN | 1 | 25 MG | 0 | |||||||||||
| 124974183 | 12497418 | 12 | C | FUROSEMID | FUROSEMIDE | 1 | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124974183 | 12497418 | 1 | Antiviral prophylaxis |
| 124974183 | 12497418 | 2 | Antiviral prophylaxis |
| 124974183 | 12497418 | 3 | Antiviral prophylaxis |
| 124974183 | 12497418 | 4 | Antiviral prophylaxis |
| 124974183 | 12497418 | 5 | Antiviral prophylaxis |
| 124974183 | 12497418 | 6 | Antiviral prophylaxis |
| 124974183 | 12497418 | 7 | Product used for unknown indication |
| 124974183 | 12497418 | 8 | Product used for unknown indication |
| 124974183 | 12497418 | 9 | Product used for unknown indication |
| 124974183 | 12497418 | 10 | Product used for unknown indication |
| 124974183 | 12497418 | 11 | Product used for unknown indication |
| 124974183 | 12497418 | 12 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124974183 | 12497418 | OT |
| 124974183 | 12497418 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124974183 | 12497418 | Corona virus infection | |
| 124974183 | 12497418 | Cryptorchism | |
| 124974183 | 12497418 | Dermatitis diaper | |
| 124974183 | 12497418 | Oxygen saturation decreased | |
| 124974183 | 12497418 | Rash maculo-papular | |
| 124974183 | 12497418 | Upper respiratory tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124974183 | 12497418 | 1 | 20151027 | 20151027 | 0 | |
| 124974183 | 12497418 | 2 | 20151221 | 20151221 | 0 | |
| 124974183 | 12497418 | 3 | 20160115 | 20160115 | 0 | |
| 124974183 | 12497418 | 4 | 20160215 | 20160215 | 0 | |
| 124974183 | 12497418 | 5 | 20160311 | 20160311 | 0 | |
| 124974183 | 12497418 | 6 | 20160408 | 20160408 | 0 | |
| 124974183 | 12497418 | 7 | 20160303 | 0 | ||
| 124974183 | 12497418 | 12 | 20160310 | 0 |